Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | IDE | P14735 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974802 | 0.85 | IDE (0.77) | MEN1KMT2AMAPTIDECASP3 | |
| SCHEMBL5704809 | 0.84 | IDE (0.60) | MEN1KMT2AMAPTIDECASP3 | |
| SCHEMBL522909 | 0.83 | MEN1 (1.00) | MEN1KMT2AMAPTIDECASP3 | |
| SCHEMBL988011 | 0.83 | MEN1 (1.00) | MEN1KMT2AMAPTIDECASP3 | |
| SCHEMBL8726508 | 0.80 | MEN1 (0.76) | MEN1KMT2AMAPTIDECASP3 | |
| SCHEMBL9618148 | 0.78 | CASP3 (0.65) | MEN1KMT2AMAPTIDECASP3 | |
| SCHEMBL31591465 | 0.78 | CASP3 (0.65) | MEN1KMT2AMAPTIDECASP3 | |
| SCHEMBL9618147 | 0.78 | CASP3 (0.65) | MEN1KMT2AMAPTIDECASP3 | |
| SCHEMBL28634056 | 0.76 | HSD17B10 (0.63) | MEN1KMT2AMAPTLMNAMYC | |
| SCHEMBL1252583 | 0.75 | IDE (0.66) | MEN1KMT2AMAPTIDECASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1769247-A1 | BIOTIN RECOGNITION SENSORS AND HIGH-THROUGHPUT ASSAYS | Molecular Probes, Inc. (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2005080989-A1 | BIOTIN RECOGNITION SENSORS AND HIGH-THROUGHPUT ASSAYS | MOLECULAR PROBES, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-5073171-A | Solid polymeric body incorporating an albumin-binding dye to form a protective coating; anticoagulants; antiinflammatory agents | EATON JOHN W (US) | 1991-12-17 | — | — | US | claimed |
| US-20210236668-A1 | COMPOSITIONS FOR RADIOTHERAPY AND USES THEREOF | UNIV COLUMBIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-10925852-B2 | Talc-bound compositions and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3765093-A1 | PROGRAMMABLE IMMUNOCYTE RECEPTOR COMPLEX SYSTEM | Fundamental Solutions Corporation (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019195466-A1 | COMPOSITIONS FOR RADIOTHERAPY AND USES THEROF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019178342-A1 | PROGRAMMABLE IMMUNOCYTE RECEPTOR COMPLEX SYSTEM | FUNDAMENTAL SOLUTIONS CORPORATION (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190216956-A1 | COMPOSITIONS FOR RADIOTHERAPY AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-07-18 | — | — | US | disclosed |
| US-10344060-B2 | Potent and selective inhibitors of Nav1.7 | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3490615-A1 | GEL-BOUND COMPOSITIONS FOR RADIOTHERAPY AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-1346730-A1 | Pretargeting methods and novel pretargeting conjugates | NEORX CORPORATION (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6217869-B1 | ADMINISTERING ANTIBODY, ANTIGEN, LIGAND COMPLEX | NEORX CORPORATION | 2001-04-17 | — | — | US | disclosed |
| US-6015897-A | FOR CONJUGATION TO LIGAND/ANTILIGAND PAIR AND USE IN DELIVERY OF THERAPEUTIC OR DIAGNOSTIC AGENT TO TARGETED SITE | NEORX CORPORATION (US) | 2000-01-18 | — | — | US | disclosed |
| WO-2000001729-A2 | SYNTHETIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR DIAGNOSIS AND TREATMENT OF ANTI-PHOSPHOLIPID SYNDROME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-01-13 | — | — | WO | disclosed |
| US-5985658-A | SEPARATING TARGET CELLS FROM A PLURALITY OF CELLS BASED ON A REVERSIBLE HIGH AFFINITY INTERACTION BETWEEN TWO MOLECULES, CALMODULIN AND A CALMODULIN BINDING PEPTIDE; SEPARATING BONE MARROW CELLS FROM T-CELLS, TUMOR CELLS FOR EXAMPLE | HEALTH RESEARCH INCORPORATED (US) | 1999-11-16 | — | — | US | disclosed |
| US-5976535-A | ADMINISTERING A FIRST CONJUGATE COMPRISING A TARGETING MOIETY AND STREPTAVIDIN; AND SUBSEQUENTLY ADMINISTERING A SECOND CONJUGATE COMPRISING A CYTOKINE AND BIOTIN, REDUCING THE ENDOGENOUS BIOTIN LEVEL | NEORX CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0733066-A4 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORP (US) | 1999-04-21 | — | — | EP | disclosed |
| EP-0733066-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015979-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10925852-B2 | Talc-bound compositions and uses thereof | SSB, UACA, TTR | MEN1 667/4885KMT2A 3904/4885MAPT 220/4885 |
| US-10344060-B2 | Potent and selective inhibitors of Nav1.7 | SCN7A, SCN9A, SCN1A | MEN1 3864/4885KMT2A 1298/4885MAPT 2414/4885 |
| US-20190216956-A1 | COMPOSITIONS FOR RADIOTHERAPY AND USES THEREOF | TP53, RAD51, MALT1 | MEN1 90/4885KMT2A 3747/4885MAPT 953/4885 |
| US-20210236668-A1 | COMPOSITIONS FOR RADIOTHERAPY AND USES THEREOF | COL1A1, COL2A1, COL14A1 | MEN1 1271/4885KMT2A 4668/4885MAPT 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.